Itonic (NASDAQ:ITOC – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.09) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.23 million during the quarter.
Itonic Price Performance
NASDAQ:ITOC opened at $0.34 on Wednesday. Itonic has a 1 year low of $0.25 and a 1 year high of $32.00.
Wall Street Analyst Weigh In
Separately, Weiss Ratings initiated coverage on Itonic in a research report on Tuesday, February 10th. They set a “sell (e+)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.
Itonic Company Profile
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.
Read More
Receive News & Ratings for Itonic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itonic and related companies with MarketBeat.com's FREE daily email newsletter.
